Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03

Breast Cancer Research and Treatment

Volumn 127, Issue 1, 2011, Pages 143-152

  Ohsumi, Shozo ^a   Shimozuma, Kojiro ^b   Ohashi, Yasuo ^c   Shinji, Megumi ^c   Hozumi, Yasuo ^d   Mukai, Hirofumi ^e   Takatsuka, Yuichi ^f   Aihara, Tomohiko ^g  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b RITSUMEIKAN UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f KANSAI ROSAI HOSPITAL   (Japan)

^g Aihara Hospital   (Japan)

Author keywords

Adjuvant endocrine therapy; Aromatase inhibitor; Breast cancer; Quality of life; Tamoxifen

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISTRESS SYNDROME; DIZZINESS; DRUG EFFICACY; ENDOCRINE DISEASE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY SCALE; HEADACHE; HEALTH SURVEY; HOT FLUSH; HUMAN; JAPANESE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; VAGINA DISCHARGE; WELLBEING;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; QUALITY OF LIFE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 79954910840     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1400-y     Document Type: Article

References (23)

1. A Howell J Cuzick M Baum A Buzdar M Dowsett JF Forbes G Hoctin-Boes J Houghton GY Locker ATAC Tobias JS Trialists' Group 2005 Results of the ATAC (Arimidex, Tamoxfen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 9453 60 62 10.1016/S0140- 6736(04)17666-6 15639680 10.1016/S0140-6736(04)17666-6 1:STN:280: DC%2BD2M%2FhsVartA%3D%3D (Pubitemid 40082147)
2. The Breast International Group (BIG) 1-98 Collaborative Group B Thurlimann A Keshaviah AS Coates H Mouridsen L Mauriac JF Forbes R Paridaens M Castiglione-Gertsch RD Gelber M Rabaglio I Smith A Wardley KN Price A Goldhirsch 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 26 2747 2757 16382061 10.1056/NEJMoa052258 (Pubitemid 43016814)
3. RC Coombes E Hall LJ Gibson R Paridaens J Jassem T Delozier SE Jones I Alvarez G Bertelli O Ortmann AS Coates E Bajetta D Dodwell RE Coleman LJ Fallowfield E Mickiewicz J Andersen PE Lonning G Cocconi A Stewart N Stuart CF Snowdon M Carpentieri G Massimini JM Bliss C van de Velde Intergroup Exemestane Study 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 11 1081 1092 15014181 10.1056/NEJMoa040331 1:CAS:528: DC%2BD2cXitV2qtbc%3D (Pubitemid 38298988)
4. RC Coombes LS Kilburn CF Snowdon R Paridaens RE Coleman SE Jones J Jassem CJ van de Velde T Delozier I Alvarez L Del Mastro O Ortmann K Diedrich AS Coates E Bajetta SB Holmberg D Dodwell E Mickiewicz J Andersen PE Lonning G Cocconi J Forbes M Castiglione N Stuart A Stewart LJ Fallowfield G Bertelli E Hall RG Bogle M Carpentieri E Colajori M Subar E Ireland JM Bliss Intergroup Exemestane Study 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial Lancet 369 9561 559 570 10.1016/S040-6736(07)60200-1 17307102 10.1016/S0140-6736(07)60200-1 1:CAS:528:DC%2BD2sXhvVGgsro%3D
5. F Boccardo A Rubagotti M Puntoni P Guglielmini D Amoroso A Fini G Paladini M Mesiti D Romeo M Rinaldini S Scall M Porpiglia C Benedetto N Restuccia F Buzzi R Franchi B Massidda V Distante D Amadori P Sismondi 2005 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial J Clin Oncol 23 22 5138 5147 10.1200/JCO.2005.04.120 16009955 10.1200/JCO.2005.04.120 1:CAS:528:DC%2BD2MXpsFWmtb4%3D (Pubitemid 46224022)
6. R Jakesz W Jonat M Gnant M Mittlboeck R Greil C Tausch J Hilfrich W Kwasny C Menzel H Samonigg M Seifert G Gademann M Kaufmann J Wolfgang ABCSG and GABG 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 9484 455 462 10.1016/S0140- 6736(05)37059-6 16084253 10.1016/S0140-6736(05)67059-6 1:CAS:528: DC%2BD2MXntVeisLw%3D (Pubitemid 41111693)
7. PE Goss JN Ingle S Martino NJ Robert HB Muss MJ Piccart M Castiglione D Tu LE Shepherd KI Prichard RB Livingston NE Davidson L Norton EA Perez JS Abrams P Therasse MJ Palmer JL Pater 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 19 1793 1802 14551341 10.1056/NEJMoa032312 1:CAS:528:DC%2BD3sXosl2gtbc%3D (Pubitemid 37362955)
8. R Jakesz R Greil M Gnant M Schmid W Kwasny E Kubista B Mlineritsch C Tausch M Stierer F Hofbauer K Renner C Dadak E Rucklinger H Samonigg Austrian Breast Colorectal Cancer Study Group 2007 Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a J Natl Cancer Inst 99 1845 1853 10.1093/jnci/djm246 18073378 10.1093/jnci/djm246 1:CAS:528:DC%2BD1cXhtVOrtL0%3D (Pubitemid 351767193)
9. EP Mamounas J-H Jeong DL Wickerham RE Smith PA Ganz SR Land A Eisen L Fehrenbacher WB Farrar JN Atkins ER Pajon VG Vogel JF Kroener LF Hutchins A Robidoux JL Hoehn JN Ingle CE Geyer Jr JP Costantino N Wolmark 2008 Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial J Clin Oncol 26 12 1965 1971 10.1200/JCO.2007.14.0228 18332472 10.1200/JCO.2007.14.0228 1:CAS:528:DC%2BD1cXlvFaqs74%3D
10. L Fallowfield D Cella J Cuzick S Francis G Locker A Howell 2004 Quality of life of postmenopausal women in the Arimidex, Tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial J Clin Oncol 22 21 4261 4271 10.1200/JCO.2004.08.029 15514369 10.1200/JCO.2004.08.029 1:CAS:528: DC%2BD2cXhtVKju7bF (Pubitemid 41185147)
11. D Cella L Fallowfield P Barker J Cuzick G Locker A Howell ATAC Trialists' Group 2006 Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer Breast Cancer Res Treat 100 3 273 284 10.1007/s10549-006-9260-6 16944295 10.1007/s10549-006- 9260-6 (Pubitemid 44707921)
12. LJ Fallowfield JM Bliss LS Porter MH Price CF Snowdon SE Jones RC Coombes E Hall 2006 Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer J Clin Oncol 24 6 910 917 10.1200/JCO.2005.03.3654 16484701 10.1200/JCO.2005.03.3654 1:CAS:528: DC%2BD28Xitl2qtrc%3D (Pubitemid 46638844)
13. TJ Whelan PE Goss JN Ingle JL Pater D Tu K Pritchard S Liu LE Shepherd M Palmer NJ Robert S Martino HB Muss 2005 Assessment of quality of life in MA. 17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenposal women J Clin Oncol 23 28 6931 6940 10.1200/JCO.2005.11.181 16157934 10.1200/JCO.2005.11.181 1:CAS:528:DC%2BD2MXhtFCrsbvJ
14. T Aihara Y Takatsuka S Ohsumi K Aogi Y Hozumi S Imoto H Mukai H Iwata T Watanabe C Shimizu K Nakagami M Tamura T Ito N Masuda N Ogino K Hisamatsu S Mitsuyama H Abe S Tanaka T Yamaguchi Y Ohashi 2010 Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer. N-SAS BC03 study Breast Cancer Res Treat 121 2 379 387 10.1007/s10549-010-0888-x 20390343 10.1007/s10549-010-0888-x 1:CAS:528:DC%2BC3cXmtlyhs7g%3D
15. H Fumimoto K Kobayashi CH Chang S Eremenco Y Fujiki S Umemura Y Ohashi S Kudoh 2001 Cross-cultural validation of an international questionnaire, the general measure of the functional assessment of cancer therapy scale (FACT-G), for Japanese Qual Life Res 10 8 701 709 10.1023/A:1013851216181 11871591 10.1023/A:1013851216181 1:STN:280:DC%2BD387js12lsw%3D%3D (Pubitemid 34145321)
16. Shimozuma K, Eguchi N Development and clinical application of QOL measurement instruments for cancer patients (I) - making Japanese versions of QOL questionnaires developed in North American or European countries and validation of reliability and validity of FACT-B, a QOL questionnaire for breast cancer patients -(in Japanese) http://www.jmari.med.or.jp/research/research. php?type=&mode=1&cno=&author=%B2%BC%BA%CA%B9%B8%C6%F3%CF%BA
17. W Jonat M Gnant F Boccardo M Kaufmann A Rubagotti I Zuna M Greenwood R Jakesz 2006 Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis Lancet Oncol 7 12 991 996 10.1016/S1470-2045(06)70948-2 17138220 10.1016/S1470-2045(06)70948-2 1:CAS:528:DC%2BD28Xht1KrsbzM (Pubitemid 44804137)
18. EP Winer C Hudis HJ Burstein AC Wolff KI Pritchard JN Ingle RT Chlebowski R Gelber SB Edge J Gralow MA Cobleigh EP Mamounas LJ Goldstein TJ Whelan TJ Powles J Bryant C Perkins J Perotti S Braun AS Langer GP Browman MR Somerfield 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004 J Clin Oncol 23 3 619 629 10.1200/JCO.2005.09.121 15545664 10.1200/JCO.2005.09.121 1:CAS:528: DC%2BD2MXitVartb4%3D (Pubitemid 46224240)
19. D Cella EA Hahn K Dineen 2002 Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening Qual Life Res 11 3 207 221 10.1023/A:1015276414526 12074259 10.1023/A:1015276414526 (Pubitemid 34553502)
20. KD Crew H Greenlee J Capodice G Raptis L Brafman D Fuentes A Sierra DL Hershman 2007 Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early stage breast cancer J Clin Oncol 25 25 3877 3883 10.1200/JCO.2007.10.7573 17761973 10.1200/JCO.2007.10.7573 (Pubitemid 47477264)
21. B Moy D Tu JL Pater JN Ingle LE Shepherd TJ Whelan PE Goss 2006 Clinical outcomes of ethnic minority women in MA. 17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer Ann Oncol 17 11 1637 1643 10.1093/annonc/mdl177 16936184 10.1093/annonc/mdl177 1:STN:280:DC%2BD28jhsFWmuw%3D%3D (Pubitemid 44680883)
22. Y Jin Z Desta V Stearns B Ward H Ho KH Lee T Skaar AM Storniolo L Li A Araba R Blanchard A Nguyen L Ullmer J Hayden S Lemier RM Weinshilboum JM Rae DF Hayes DA Flockhart 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 1 30 39 10.1093/jnci/dji005 15632378 10.1093/jnci/dji005 1:CAS:528: DC%2BD2MXisVaqsw%3D%3D
23. Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, Hozumi Y (2009) Health-related quality of life and psychological distress in Japanese postmenopausal women with breast cancer treated with tamoxifen, exemestane or anastrozole for adjuvant endocrine therapy: a final analysis of National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04. Cancer Res 69(24) (suppl 3) (abstr 5041)